Brief Title
Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)
Official Title
AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SAFETY DATA OF FACTOR IX OR FACTOR VIII PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS (FIX:C≤2%) WHO ARE NEGATIVE FOR nAb TO AAV VECTOR-SPARK100 AND MODERATELY SEVERE TO SEVERE HEMOPHILIA A ADULT SUBJECTS (FVIII:C≤1%) WHO ARE NEGATIVE FOR nAb to AAV VECTOR SB-525 CAPSID (AAV6), PRIOR TO THE RESPECTIVE THERAPEUTIC PH 3 GENE THERAPY STUDIES (See Detailed Description Section for Official Protocol Title)
Brief Summary
To establish a minimum of 6 months of prospective efficacy data of current FIX prophylaxis
replacement therapy in the usual care setting of hemophilia B subjects, who are negative for
nAb to AAV-Spark100, prior to the Phase 3 gene therapy study.
To establish a minimum of 6 months of prospective efficacy data of current FVIII prophylaxis
replacement therapy in the usual care setting of hemophilia A subjects, who are negative for
nAb to SB-525 capsid (AAV6), prior to the Phase 3 gene therapy study.
The enrollment for hemophilia B participants is completed. At this time participants are only
being enrolled for hemophilia A cohort.
Detailed Description
AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, MULTI-CENTER, LEAD-IN STUDY TO EVALUATE AT LEAST
6 MONTHS OF PROSPECTIVE EFFICACY AND SELECTED SAFETY DATA OF CURRENT FACTOR IX (FIX) OR
FACTOR VIII (FVIII) PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY
SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS (FIX:C≤2%) WHO ARE NEGATIVE FOR NEUTRALIZING
ANTIBODIES TO ADENO-ASSOCIATED VIRUS VECTOR-SPARK100 (BENEGENE-1) AND MODERATELY SEVERE TO
SEVERE HEMOPHILIA A ADULT SUBJECTS (FVIII:C≤1%) WHO ARE NEGATIVE FOR NEUTRALIZING ANTIBODIES
TO ADENO-ASSOCIATED VIRUS VECTOR SB-525 CAPSID (AAV6), PRIOR TO THE RESPECTIVE THERAPEUTIC
PHASE 3 GENE THERAPY STUDIES
Study Phase
Phase 3
Study Type
Interventional
Primary Outcome
Annualized bleeding rate (ABR)
Secondary Outcome
Annualized infusion rate (AIR)
Condition
Hemophilia B
Intervention
Standard of Care FIX Replacement therapy
Study Arms / Comparison Groups
Standard of Care FIX replacement therapy
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
250
Start Date
July 26, 2018
Completion Date
July 13, 2022
Primary Completion Date
July 13, 2022
Eligibility Criteria
Inclusion Criteria:
Hemophilia B Population:
1. Evidence of a personally signed and dated informed consent document indicating that
the subject has been informed of all pertinent aspects of the study.
2. Willing and able to comply with scheduled visits, FIX prophylaxis treatment plan,
laboratory tests and other study procedures.
3. Males ≥ 18 and <65 years of age with moderately severe to severe hemophilia B and
documented FIX activity (≤2%) prior to baseline visit.
4. Previous experience with FIX therapy (≥50 documented exposure days to a FIX protein
product such as recombinant, plasma-derived or extended half-life FIX product).
5. Subjects on FIX prophylaxis replacement therapy (recombinant, plasma-derived or
extended half-life FIX product) must have the intention to remain on FIX prophylaxis
replacement therapy for the duration of the study.
6. No known hypersensitivity to FIX replacement product.
7. No history of FIX inhibitor (clinical or laboratory-based assessment) defined as a
titer
- 0.6 BU/mL, regardless of the laboratory normal range, or any measured Bethesda
inhibitor titer greater than the upper limit of normal for the laboratory
performing the assay. Clinically, no signs or symptoms of decreased response to
FIX administration. Subjects will not be required to undergo diagnostic
evaluation of inhibitor status to participate in the study.
Hemophilia A Population:
1. Evidence of a personally signed and dated informed consent document indicating that
the subject has been informed of all pertinent aspects of the study.
2. Willing and able to comply with scheduled visits, FVIII prophylaxis treatment plan,
laboratory tests and other study procedures.
3. Males ≥18 and <65 years of age with moderately severe to severe hemophilia A and
documented FVIII activity (≤1%) prior to baseline visit.
4. Previous experience with FVIII therapy (≥150 documented exposure days to a FVIII
protein product such as recombinant, plasma-derived or extended half-life FVIII
product).
5. Subjects on FVIII prophylaxis replacement therapy (recombinant, plasma-derived or
extended half-life FVIII product) must have the intention to remain on FVIII
prophylaxis replacement therapy for the duration of the study.
6. No known hypersensitivity to FVIII replacement product.
7. No history of FVIII inhibitor (clinical or laboratory-based assessment) defined as a
titer ≥0.6 BU/mL, regardless of the laboratory normal range, or any measured Bethesda
inhibitor titer greater than the upper limit of normal for the laboratory performing
the assay. Clinically, no signs or symptoms of decreased response to FVIII
administration. Subjects will not be required to undergo diagnostic evaluation of
inhibitor status to participate in the study.
Exclusion Criteria:
1. Anti-AAV-Spark100 neutralizing antibody titer above or equal to 1:1 performed by a
central laboratory during screening in hemophilia B subjects or Anti- SB-525 capsid
(AAV6) neutralizing antibody titer (above or equal to the lowest detectable titer)
performed by a central laboratory during screening in hemophilia A subjects.
2. Lack of patient compliance with documentation of bleeds and/or prophylaxis replacement
therapy administration.
3. If there is no documentation regarding hepatitis status, as defined below, within the
last 12 months prior to screening for hepatitis B and 6 months prior to screening for
hepatitis C, then subjects will be required to have the following hepatitis testing
performed at screening:
1. Hepatitis B screening (acute and chronic):
HBsAg (also referred to as Hepatitis B surface antigen), HBV-DNA viral assay
(also referred to as a nucleic acid test for Hepatitis B virus DNA), and Anti-HBc
(also referred to as Total Hepatitis B core antibody).
- A subject is not eligible if either HbsAg is positive or HBV-DNA is
positive/detectable.
- Anti-HBc must be obtained in all subjects for determination of whether the
subject had prior hepatitis B. If the anti-HBc is positive and both HBsAg
and HBV DNA are negative this would be consistent with a prior infection and
the subject would be eligible for the study. Anti-HBc must be obtained in
all subjects to discriminate between those with no prior hepatitis B and
those with prior infection in the event of reactivation. FDA has noted
reactivation of hepatitis B virus exists.
- One documented negative HBV-DNA viral load is sufficient to assess
eligibility. A subject who is currently undergoing anti-viral therapy for
hepatitis B is not eligible.
2. Hepatitis C (acute or chronic):
- A subject who is currently undergoing anti-viral therapy for chronic
hepatitis C is not eligible.
- Subjects treated with anti-viral therapy for chronic hepatitis C, must have
completed anti-viral therapy at least 6 months prior to screening and have a
negative HCV-RNA at least 6 months prior to screening.
- All subjects (who are not currently undergoing anti-viral therapy for
chronic hepatitis C) must have a single HCV-RNA load assay (also referred to
as a nucleic acid test [NAT] for HCV RNA) obtained during the 6 months
preceding screening. This includes subjects with prior known chronic
hepatitis C who have completed treatment with anti-viral therapy.
- A subject is not eligible if his HCV-RNA load assay result is
positive/detectable.
4. Currently on antiviral therapy for hepatitis B or C.
5. A subject is not eligible if any of the following pre-existing diagnoses, which are
indicative of significant underlying liver disease, are present in the medical record:
- Portal hypertension; or
- Splenomegaly; or
- Hepatic encephalopathy.
All subjects who do not have the listed pre-existing diagnoses above must have the
following assessments performed within the last 12 months prior to screening and if
not will need to be tested for liver fibrosis status at screening:
- Measurement of serum albumin. A subject is not eligible if the serum albumin
level is below the testing laboratory's lower limit of normal; and
- One of the following diagnostic tests for liver fibrosis. The following results
are indicative of fibrosis and exclude the subject from participation:
- FibroScan, with a score >8.3 kPa units;
- FibroTest/FibroSURE with a result >0.48*; or
- AST-to-Platelet Ratio Index (APRI) >1.
- Please note, if a subject has a known history of Gilbert's syndrome, a
FibroTest cannot be used for fibrosis testing.
6. Documented serological evidence of human immunodeficiency virus HIV-1 or HIV-2 with
Cluster of Differentiation 4 positive (CD4+) cell count ≤200 mm3 within the last 12
months prior to screening. Subjects who are HIV positive and stable, have an adequate
CD4 count (>200/mm3) and undetectable viral load (<50 gc/mL) documented within the
preceding 12 months, and are on an antiretroviral drug regimen are eligible to enroll.
Subjects who have not been tested within the prior 12 months of screening will need to
be tested for HIV status at screening.
7. History of chronic infection or other chronic disease that the investigator deems an
unacceptable risk. Any patient with a history of thrombotic events including but not
limited to stroke or myocardial infarction.
8. Any concurrent clinically significant major disease or condition that the investigator
deems unsuitable for participation or other acute or chronic medical or psychiatric
condition including recent (within the past year) or active suicidal ideation or
behavior or laboratory abnormality that may increase the risk associated with study
participation or may interfere with the interpretation of study results and, in the
judgment of the investigator, would make the subject inappropriate for entry into this
study.
9. Participation in other studies involving investigational drug(s) within the last 3
months prior to study entry and/or during study participation or in a previous gene
therapy clinical study within the last 12 months prior to screening.
10. Any subject who previously received fidanacogene elaparvovec (SPK-9001) (hemophilia B)
or SB-525 (hemophilia A) or any AAV gene-based therapy.
11. Any subject with a planned surgical procedure requiring FIX (hemophilia B) or FVIII
(hemophilia A) surgical prophylactic factor treatment in the next 24 months.
12. Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
subjects who are Pfizer employees, including their family members, directly involved
in the conduct of the study.
Gender
Male
Ages
18 Years - 64 Years
Accepts Healthy Volunteers
No
Contacts
Pfizer CT.gov Call Center, 1-800-718-1021, [email protected]
Location Countries
Australia
Location Countries
Australia
Administrative Informations
NCT ID
NCT03587116
Organization ID
C0371004
Secondary IDs
2017-001271-23
Responsible Party
Sponsor
Study Sponsor
Pfizer
Study Sponsor
Pfizer CT.gov Call Center, Study Director, Pfizer
Verification Date
October 2020